MedTrace Logo

Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease

NCT01265524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2013-03-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease.

Conditions

Interventions

DRUG

CLP

Oral administration

DRUG

Placebo

Oral administration

Sponsors & Collaborators

  • Pharmaterra

    collaborator UNKNOWN

  • Sorbent Therapeutics

    lead INDUSTRY

Principal Investigators

  • Detlef Albrecht, MD · Sorbent Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-11-30

Countries

  • Armenia
  • Georgia
  • Moldova

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01265524 on ClinicalTrials.gov